Cargando…

GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA

BACKGROUND: Localized NGGCT, a heterogeneous entity, treated with chemo-radiotherapy harbors an overall survival of around 93% based. Here, we present a case of a child whose immature teratoma progressed on chemotherapy, while tumor markers remain within normal range. Salvage therapy for progressive...

Descripción completa

Detalles Bibliográficos
Autores principales: McNutt, Sarah, Shah, Nidhi, Rizk, Elias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263156/
http://dx.doi.org/10.1093/neuonc/noab090.064
_version_ 1783719328520077312
author McNutt, Sarah
Shah, Nidhi
Rizk, Elias
author_facet McNutt, Sarah
Shah, Nidhi
Rizk, Elias
author_sort McNutt, Sarah
collection PubMed
description BACKGROUND: Localized NGGCT, a heterogeneous entity, treated with chemo-radiotherapy harbors an overall survival of around 93% based. Here, we present a case of a child whose immature teratoma progressed on chemotherapy, while tumor markers remain within normal range. Salvage therapy for progressive immature teratoma is variable, and can include surgery, chemotherapy and/or craniospinal radiation. Case: 10 year old boy with precocious puberty presented to the local Emergency room with tonic-clonic seizures. Imaging showed a localized pineal mass, with mixed cystic and solid components. Biopsy results were diagnostic for mixed germ cell tumor with components of immature teratoma. Prior to the start of chemotherapy, serum and cerebrospinal fluid (CSF) tumor markers showed slight elevation of both alpha feto- protein (AFP) and beta-human chorionic gonadotropin hormone (β-HCG). The patient underwent two cycles of chemotherapy per ACNS1123, stratum 1, with normalization of tumor markers. Unfortunately, near the end of Cycle 2 of chemotherapy, patient presented with clinical signs of herniation, and was noted to have significant progression of pineal mass on imaging. Tumor was gross totally resected, with pathology conclusive for only immature teratoma. Pre- and post-operative tumor markers remained normal. Proton-beam craniospinal radiation was then administered. Patient is now almost 6 months off therapy, with unremarkable serum and CSF tumor markers, as well as serial imaging that remains negative for disease, with neurological development appropriate for age. CONCLUSION: This case highlights the unusual nature of progression of an immature teratoma with no elevation of tumor markers while on chemotherapy. While salvage chemotherapy, in the form of a metronomic regimen or high-dose consolidative regimen, can be considered, these do present quite a bit of short-term and long-term toxicity to the growing child. Craniospinal irradiation followed by close monitoring is a reasonable alternative, with less short-term toxicity, for an entity that is radio-sensitive.
format Online
Article
Text
id pubmed-8263156
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-82631562021-07-08 GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA McNutt, Sarah Shah, Nidhi Rizk, Elias Neuro Oncol Germ Cell Tumors BACKGROUND: Localized NGGCT, a heterogeneous entity, treated with chemo-radiotherapy harbors an overall survival of around 93% based. Here, we present a case of a child whose immature teratoma progressed on chemotherapy, while tumor markers remain within normal range. Salvage therapy for progressive immature teratoma is variable, and can include surgery, chemotherapy and/or craniospinal radiation. Case: 10 year old boy with precocious puberty presented to the local Emergency room with tonic-clonic seizures. Imaging showed a localized pineal mass, with mixed cystic and solid components. Biopsy results were diagnostic for mixed germ cell tumor with components of immature teratoma. Prior to the start of chemotherapy, serum and cerebrospinal fluid (CSF) tumor markers showed slight elevation of both alpha feto- protein (AFP) and beta-human chorionic gonadotropin hormone (β-HCG). The patient underwent two cycles of chemotherapy per ACNS1123, stratum 1, with normalization of tumor markers. Unfortunately, near the end of Cycle 2 of chemotherapy, patient presented with clinical signs of herniation, and was noted to have significant progression of pineal mass on imaging. Tumor was gross totally resected, with pathology conclusive for only immature teratoma. Pre- and post-operative tumor markers remained normal. Proton-beam craniospinal radiation was then administered. Patient is now almost 6 months off therapy, with unremarkable serum and CSF tumor markers, as well as serial imaging that remains negative for disease, with neurological development appropriate for age. CONCLUSION: This case highlights the unusual nature of progression of an immature teratoma with no elevation of tumor markers while on chemotherapy. While salvage chemotherapy, in the form of a metronomic regimen or high-dose consolidative regimen, can be considered, these do present quite a bit of short-term and long-term toxicity to the growing child. Craniospinal irradiation followed by close monitoring is a reasonable alternative, with less short-term toxicity, for an entity that is radio-sensitive. Oxford University Press 2021-06-01 /pmc/articles/PMC8263156/ http://dx.doi.org/10.1093/neuonc/noab090.064 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Germ Cell Tumors
McNutt, Sarah
Shah, Nidhi
Rizk, Elias
GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA
title GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA
title_full GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA
title_fullStr GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA
title_full_unstemmed GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA
title_short GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA
title_sort germ-02. management strategy for chemo-refractory, progressive pediatric immature teratoma
topic Germ Cell Tumors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263156/
http://dx.doi.org/10.1093/neuonc/noab090.064
work_keys_str_mv AT mcnuttsarah germ02managementstrategyforchemorefractoryprogressivepediatricimmatureteratoma
AT shahnidhi germ02managementstrategyforchemorefractoryprogressivepediatricimmatureteratoma
AT rizkelias germ02managementstrategyforchemorefractoryprogressivepediatricimmatureteratoma